Ontology highlight
ABSTRACT:
SUBMITTER: Zhang J
PROVIDER: S-EPMC6930858 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
Zhang Jason J Sanghavi Kinjal K Shen Jun J Zhao Xiaochen X Feng Yan Y Statkevich Paul P Sheng Jennifer J Roy Amit A Zhu Li L
CPT: pharmacometrics & systems pharmacology 20191201 12
Nivolumab is a fully human monoclonal antibody that inhibits programmed cell death-1 activation. To assess covariate effects on nivolumab clearance (CL), a population pharmacokinetics model was developed using data from 6,468 patients with colorectal cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, renal cell carcinoma, or small cell lung cancer who received nivolumab as monotherapy or in combination with ipilimumab or chemotherapy across 25 clinical studies. Nivolumab CL ...[more]